Summary

In 2024, the global market size of Myotonic Dystrophy Drug was estimated to be worth US$ 47.9 million and is forecast to reach approximately US$ 75.4 million by 2031 with a CAGR of 6.8% during the forecast period 2025-2031.
Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Drug.
The Myotonic Dystrophy Drug market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Myotonic Dystrophy Drug market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myotonic Dystrophy Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and regions.

By Company
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
Segment by Type
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Myotonic Dystrophy Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Myotonic Dystrophy Drug sales, revenue, price, gross margin, sales by region, by Type, by Distribution Channel, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Distribution Channel, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Distribution Channel and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Myotonic Dystrophy Drug Product Introduction
1.2 Market by Type
1.2.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Sodium Channel Blocker
1.2.3 Tricyclic Antidepressant
1.2.4 Other
1.3 Market by Distribution Channel
1.3.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Distribution Channel (2020 VS 2024 VS 2031)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Myotonic Dystrophy Drug Market Size Estimates and Forecasts
2.1.1 Global Myotonic Dystrophy Drug Revenue 2020-2031
2.1.2 Global Myotonic Dystrophy Drug Sales 2020-2031
2.2 Myotonic Dystrophy Drug Market Size by Region: 2024 Versus 2031
2.3 Myotonic Dystrophy Drug Sales by Region (2020-2031)
2.3.1 Global Myotonic Dystrophy Drug Sales by Region: 2020-2025
2.3.2 Global Myotonic Dystrophy Drug Sales Forecast by Region (2026-2031)
2.3.3 Global Myotonic Dystrophy Drug Sales Market Share by Region (2020-2031)
2.4 Myotonic Dystrophy Drug Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Myotonic Dystrophy Drug Revenue by Region: 2020-2025
2.4.2 Global Myotonic Dystrophy Drug Revenue Forecast by Region (2026-2031)
2.4.3 Global Myotonic Dystrophy Drug Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Myotonic Dystrophy Drug Sales by Type (2020-2031)
3.1.1.1 Global Myotonic Dystrophy Drug Sales Volume by Type (2020-2031)
3.1.1.2 Global Myotonic Dystrophy Drug Sales Market Share by Type (2020-2031)
3.1.2 Global Myotonic Dystrophy Drug Revenue by Type (2020-2031)
3.1.2.1 Global Myotonic Dystrophy Drug Revenue by Type (2020-2031)
3.1.2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2020-2031)
3.1.3 Myotonic Dystrophy Drug Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Distribution Channel
3.2.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2020-2031)
3.2.1.1 Global Myotonic Dystrophy Drug Sales Volume by Distribution Channel (2020-2031)
3.2.1.2 Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2020-2031)
3.2.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2020-2031)
3.2.2.1 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2020-2031)
3.2.2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2020-2031)
3.2.3 Myotonic Dystrophy Drug Average Selling Price (ASP) by Distribution Channel (2020-2031)
3.3 by Type and by Distribution Channel Crossing Analysis
3.3.1 Sodium Channel Blocker of Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel
3.3.2 Tricyclic Antidepressant of Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel
3.3.3 Other of Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel
4 Global Myotonic Dystrophy Drug by Manufacturers
4.1 Global Top Myotonic Dystrophy Drug Manufacturers by Sales (2020-2025)
4.1.1 Global Myotonic Dystrophy Drug Sales by Manufacturer (2020-2025)
4.1.2 Global Myotonic Dystrophy Drug Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Myotonic Dystrophy Drug Manufacturers by Revenue (2020-2025)
4.2.1 Global Myotonic Dystrophy Drug Revenue by Manufacturer (2020-2025)
4.2.2 Global Myotonic Dystrophy Drug Revenue Share by Manufacturer (2020-2025)
4.3 Global Myotonic Dystrophy Drug Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Myotonic Dystrophy Drug Manufacturers Covered: Ranking by Revenue
4.4.2 Global Myotonic Dystrophy Drug Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Myotonic Dystrophy Drug Manufacturing Base Distribution, Product Type
4.5.1 Myotonic Dystrophy Drug Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Myotonic Dystrophy Drug Market
4.5.3 Manufacturers Myotonic Dystrophy Drug Product Type and Application
4.5.4 Sodium Channel Blocker Market Sales of Myotonic Dystrophy Drug by Manufacturer
4.5.5 Tricyclic Antidepressant Market Sales of Myotonic Dystrophy Drug by Manufacturer
4.5.6 Other Market Sales of Myotonic Dystrophy Drug by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Lupin
5.1.1 Lupin Company Information
5.1.2 Lupin Description, Business Overview
5.1.3 Lupin Myotonic Dystrophy Drug Products Offered
5.1.4 Lupin Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Lupin Myotonic Dystrophy Drug Sales by Product in 2024
5.1.6 Lupin Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.1.7 Lupin Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.1.8 Lupin Recent Developments
5.2 Teva
5.2.1 Teva Company Information
5.2.2 Teva Description, Business Overview
5.2.3 Teva Myotonic Dystrophy Drug Products Offered
5.2.4 Teva Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Teva Myotonic Dystrophy Drug Sales by Product in 2024
5.2.6 Teva Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.2.7 Teva Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.2.8 Teva Recent Developments
5.3 ANI Pharmaceuticals
5.3.1 ANI Pharmaceuticals Company Information
5.3.2 ANI Pharmaceuticals Description, Business Overview
5.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Products Offered
5.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.3.5 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales by Product in 2024
5.3.6 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.3.7 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.3.8 ANI Pharmaceuticals Recent Developments
5.4 Mylan
5.4.1 Mylan Company Information
5.4.2 Mylan Description, Business Overview
5.4.3 Mylan Myotonic Dystrophy Drug Products Offered
5.4.4 Mylan Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.4.5 Mylan Myotonic Dystrophy Drug Sales by Product in 2024
5.4.6 Mylan Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.4.7 Mylan Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.4.8 Mylan Recent Developments
5.5 Novartis
5.5.1 Novartis Company Information
5.5.2 Novartis Description, Business Overview
5.5.3 Novartis Myotonic Dystrophy Drug Products Offered
5.5.4 Novartis Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Novartis Myotonic Dystrophy Drug Sales by Product in 2024
5.5.6 Novartis Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.5.7 Novartis Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.5.8 Novartis Recent Developments
5.6 Sun Pharma
5.6.1 Sun Pharma Company Information
5.6.2 Sun Pharma Description, Business Overview
5.6.3 Sun Pharma Myotonic Dystrophy Drug Products Offered
5.6.4 Sun Pharma Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Sun Pharma Myotonic Dystrophy Drug Sales by Product in 2024
5.6.6 Sun Pharma Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.6.7 Sun Pharma Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.6.8 Sun Pharma Recent Developments
5.7 Mallinckrodt
5.7.1 Mallinckrodt Company Information
5.7.2 Mallinckrodt Description, Business Overview
5.7.3 Mallinckrodt Myotonic Dystrophy Drug Products Offered
5.7.4 Mallinckrodt Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Mallinckrodt Myotonic Dystrophy Drug Sales by Product in 2024
5.7.6 Mallinckrodt Myotonic Dystrophy Drug Sales by Distribution Channel in 2024
5.7.7 Mallinckrodt Myotonic Dystrophy Drug Sales by Geographic Area in 2024
5.7.8 Mallinckrodt Recent Developments
6 North America
6.1 North America Myotonic Dystrophy Drug Market Size YoY Growth 2020-2031
6.2 North America Myotonic Dystrophy Drug Market Facts & Figures by Country
6.2.1 North America Myotonic Dystrophy Drug Sales by Country (2020-2031)
6.2.2 North America Myotonic Dystrophy Drug Revenue by Country (2020-2031)
6.3 North America Myotonic Dystrophy Drug Sales by Type (2020-2025)
6.4 North America Myotonic Dystrophy Drug Sales by Distribution Channel (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Myotonic Dystrophy Drug Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Myotonic Dystrophy Drug Market Facts & Figures by Region
7.2.1 Asia-Pacific Myotonic Dystrophy Drug Sales by Region (2020-2031)
7.2.2 Asia-Pacific Myotonic Dystrophy Drug Revenue by Region (2020-2031)
7.3 Asia-Pacific Myotonic Dystrophy Drug Sales by Type (2020-2025)
7.4 Asia-Pacific Myotonic Dystrophy Drug Sales by Distribution Channel (2020-2025)
8 Europe
8.1 Europe Myotonic Dystrophy Drug Market Size YoY Growth 2020-2031
8.2 Europe Myotonic Dystrophy Drug Market Facts & Figures by Country
8.2.1 Europe Myotonic Dystrophy Drug Sales by Country (2020-2031)
8.2.2 Europe Myotonic Dystrophy Drug Revenue by Country (2020-2031)
8.3 Europe Myotonic Dystrophy Drug Sales by Type (2020-2025)
8.4 Europe Myotonic Dystrophy Drug Sales by Distribution Channel (2020-2025)
9 Latin America
9.1 Latin America Myotonic Dystrophy Drug Market Size YoY Growth 2020-2031
9.2 Latin America Myotonic Dystrophy Drug Market Facts & Figures by Country
9.2.1 Latin America Myotonic Dystrophy Drug Sales by Country (2020-2031)
9.2.2 Latin America Myotonic Dystrophy Drug Revenue by Country (2020-2031)
9.3 Latin America Myotonic Dystrophy Drug Sales by Type (2020-2025)
9.4 Latin America Myotonic Dystrophy Drug Sales by Distribution Channel (2020-2025)
10 Middle East and Africa
10.1 Latin America Myotonic Dystrophy Drug Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Country
10.2.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2020-2031)
10.2.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2020-2031)
10.3 Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2020-2025)
10.4 Middle East and Africa Myotonic Dystrophy Drug Sales by Distribution Channel (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Myotonic Dystrophy Drug Supply Chain Analysis
11.2 Myotonic Dystrophy Drug Key Raw Materials and Upstream Suppliers
11.3 Myotonic Dystrophy Drug Clients Analysis
11.4 Myotonic Dystrophy Drug Sales Channel and Sales Model Analysis
11.4.1 Myotonic Dystrophy Drug Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Myotonic Dystrophy Drug Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Myotonic Dystrophy Drug Distributors
12 Myotonic Dystrophy Drug Market Dynamics
12.1 Myotonic Dystrophy Drug Industry Trends
12.2 Myotonic Dystrophy Drug Market Drivers
12.3 Myotonic Dystrophy Drug Market Challenges
12.4 Myotonic Dystrophy Drug Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer